全文获取类型
收费全文 | 15989篇 |
免费 | 1610篇 |
国内免费 | 201篇 |
专业分类
耳鼻咽喉 | 288篇 |
儿科学 | 461篇 |
妇产科学 | 331篇 |
基础医学 | 1839篇 |
口腔科学 | 391篇 |
临床医学 | 1905篇 |
内科学 | 2976篇 |
皮肤病学 | 234篇 |
神经病学 | 991篇 |
特种医学 | 510篇 |
外科学 | 2049篇 |
综合类 | 1364篇 |
现状与发展 | 2篇 |
一般理论 | 7篇 |
预防医学 | 1794篇 |
眼科学 | 221篇 |
药学 | 1293篇 |
2篇 | |
中国医学 | 342篇 |
肿瘤学 | 800篇 |
出版年
2022年 | 189篇 |
2021年 | 338篇 |
2020年 | 246篇 |
2019年 | 247篇 |
2018年 | 242篇 |
2017年 | 256篇 |
2016年 | 218篇 |
2015年 | 349篇 |
2014年 | 426篇 |
2013年 | 575篇 |
2012年 | 858篇 |
2011年 | 895篇 |
2010年 | 637篇 |
2009年 | 585篇 |
2008年 | 767篇 |
2007年 | 811篇 |
2006年 | 773篇 |
2005年 | 684篇 |
2004年 | 623篇 |
2003年 | 591篇 |
2002年 | 526篇 |
2001年 | 457篇 |
2000年 | 548篇 |
1999年 | 369篇 |
1998年 | 165篇 |
1997年 | 135篇 |
1996年 | 140篇 |
1995年 | 123篇 |
1994年 | 119篇 |
1993年 | 102篇 |
1992年 | 301篇 |
1991年 | 291篇 |
1990年 | 266篇 |
1989年 | 272篇 |
1988年 | 226篇 |
1987年 | 221篇 |
1986年 | 256篇 |
1985年 | 229篇 |
1984年 | 191篇 |
1983年 | 144篇 |
1982年 | 126篇 |
1979年 | 183篇 |
1978年 | 117篇 |
1977年 | 120篇 |
1975年 | 121篇 |
1974年 | 145篇 |
1973年 | 135篇 |
1972年 | 142篇 |
1971年 | 122篇 |
1970年 | 111篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
2.
Victoria L. Parker Matthew C. Winter John A. Tidy Barry W. Hancock Julia E. Palmer Naveed Sarwar Baljeet Kaur Katie McDonald Xianne Aguiar Kamaljit Singh Nick Unsworth Imran Jabbar Allan A. Pacey Robert F. Harrison Michael J. Seckl 《International journal of cancer. Journal international du cancer》2023,152(5):986-997
Gestational trophoblastic neoplasia (GTN) patients are treated according to the eight-variable International Federation of Gynaecology and Obstetrics (FIGO) scoring system, that aims to predict first-line single-agent chemotherapy resistance. FIGO is imperfect with one-third of low-risk patients developing disease resistance to first-line single-agent chemotherapy. We aimed to generate simplified models that improve upon FIGO. Logistic regression (LR) and multilayer perceptron (MLP) modelling (n = 4191) generated six models (M1-6). M1, all eight FIGO variables (scored data); M2, all eight FIGO variables (scored and raw data); M3, nonimaging variables (scored data); M4, nonimaging variables (scored and raw data); M5, imaging variables (scored data); and M6, pretreatment hCG (raw data) + imaging variables (scored data). Performance was compared to FIGO using true and false positive rates, positive and negative predictive values, diagnostic odds ratio, receiver operating characteristic (ROC) curves, Bland-Altman calibration plots, decision curve analysis and contingency tables. M1-6 were calibrated and outperformed FIGO on true positive rate and positive predictive value. Using LR and MLP, M1, M2 and M4 generated small improvements to the ROC curve and decision curve analysis. M3, M5 and M6 matched FIGO or performed less well. Compared to FIGO, most (excluding LR M4 and MLP M5) had significant discordance in patient classification (McNemar's test P < .05); 55-112 undertreated, 46-206 overtreated. Statistical modelling yielded only small gains over FIGO performance, arising through recategorisation of treatment-resistant patients, with a significant proportion of under/overtreatment as the available data have been used a priori to allocate primary chemotherapy. Streamlining FIGO should now be the focus. 相似文献
3.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献
4.
目的:应用99mTc-DTPA肾动脉显像评价Stanford不同分型主动脉夹层患者术后左、右侧肾功能及总体肾功能受损程度,帮助临床制定进一步的治疗方案,改善患者预后。方法:回顾性分析2018年3月8日至2019年7月19日,在本院核医学科行99mTc-DTPA肾动态显像的主动脉夹层术后患者48例,评价患者双肾血流灌注、总肾小球滤过率(GFR)和分肾的GFR,比较Stanford主动脉夹层A型(简称A型)患者和主动脉夹层B型(简称B型)患者之间总肾功能及分肾功能,血肌酐、血尿素氮及血尿酸水平的差异。结果:B型患者术后总GFR低于A型患者(67.5 vs.80.6 m L/min,P<0.05),其中以左肾功能受损为著(30.9 vs.40.3 m L/min,P<0.05),差异有统计学意义。结论:肾动态显像对主动脉夹层术后患者早期评价肾功能有重要价值。主动脉夹层B型患者GFR较A型减低,且左侧肾GFR减低更明显,临床可以早期采取干预措施,改善主动脉夹层患者预后。 相似文献
5.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance. 相似文献
6.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
7.
痤疮可辨为阴、阳两证。阳疮者,缘患者劳汗被寒、玄府闭合,汗脂凝聚日久不得外排,蕴热搏结气血而生疮化腐,疮症为热为痛,此为易治;阴疮者,由阳疮转化而来,缘患者外感寒风、内伤生冷,且医者又重用寒凉、失于托透,以至气血冰凝,久不溃脓或溃脓难出,此为难治。根据难治性痤疮临床表现,其多类属于阴疮,以阳虚表郁、邪闭毛窍为致病之关键,其中表郁毛窍、邪闭肌腠为病之标,阳虚阴凝为病之本。治疗当以温阳透发、祛邪外达为法。以麻黄附子细辛汤温阳化阴滞、发阳透毒治其本,待阴邪发越,即用火针强开门户、消疮排脓治其标。标本兼治、针药结合的方法治疗难治性痤疮在临床中能够安全有效地消除痤疮、改善皮损、降低复发率。 相似文献
9.
GIUSEPPE BORIANI MAURO BIFFI MAURIZIO RUSSO† MAURIZIO LUNATI‡ GIANLUCA BOTTO¶ ALESSANDRO PROCLEMER§ GIUSEPPE VERGARA WERNER RAHUE†† CRISTIAN MARTIGNANI RENATO RICCI† MASSIMO SANTINI† On Behalf of the SEARCH MI Registry Italian Investigators 《Pacing and clinical electrophysiology : PACE》2006,29(S2):S29-S34
Background: Large randomized trials show that in appropriately selected patients with left ventricular dysfunction, implantable cardioverter-defibrillators (ICDs) can improve overall survival at 2–5 years. Since direct implementation of the criteria used in the MADIT II and SCD-HeFT will lead to a marked rise in ICD implants, there is a growing fear that increased use of ICDs may cause a dramatic burden to health care systems. The ICD has traditionally been seen as an expensive form of treatment, which is difficult to accept at the first look. This is mainly due to the nonlinear character of the ICD investment, characterized by high initial expenditure, followed by a deferred pay-off in terms of clinical benefits. Cost-effectiveness analysis may help provide a different perspective on the problem of ICD cost, as may estimation of the daily cost of ICD treatment, assuming a time horizon of 5–7 years—a particularly interesting subject for further registry studies.
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
Methods and Results: Based on real expenditure data from 2002 to 2005, as recorded in the Search-MI Registry-Italian Sub-study of patients implanted on MADIT II indications, we estimated the daily costs associated with the device and leads. Over a 5–7 year time horizon, the average daily cost was estimated to be €4.60–€6.70. Translation of these figures into U.S. market conditions suggests a daily cost of around $7.90–$11.40.
Conclusions: These findings appear useful to help evaluate the affordability of ICD in comparison with other therapeutic options in a context of limited available economic resources. 相似文献
10.
目的 探讨P16、P15、P14基因5'CpG岛在膀胱移行细胞癌中甲基化状态及其临床意义。方法 应用甲基化特异性PCR(methylation—specific PCR,MSP)方法检测40例膀胱移行细胞癌P16、P15、P14基因甲基化程度,χ^2检验分析其甲基化程度与膀胱癌病理分级分期间关系。结果 膀胱移行细胞癌P16、P15、P14 5'CpG岛甲基化扩增阳性化率分别为27.5%、17.5%、35%,而正常膀胱组织中均未检测到三种基因5'CpG岛甲基化。P16、P14基因甲基化与膀胱癌病理分级分期有显著性差异(P〈0.05),P15基因则没有显著性差异(P〉0.05)。结论 P16、P15、P14基因在膀胱癌组织中的甲基化率较高,三种抑癌基因5'CpG岛异常高甲基化,在膀胱癌的发生、发展中具有重要作用。 相似文献